Mustang Bio Inc (NASDAQ:MBIO)
| 2.44 Delayed Data As of Sep 20 |  -0.04 / -1.64%Today’s Change | 2.39 Today|||52-Week Range 11.08 | -58.81% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $20.7M |
Company Description
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
Contact Information
Mustang Bio, Inc. 377 Plantation Street Worcester Massachusetts 01605-2245 |
Employees
Shareholders
| Other institutional | 5.08% |
| Mutual fund holders | 4.56% |
| Individual stakeholders | 3.16% |
Top Executives
| Manuel Litchman | President, Chief Executive Officer & Director |
| Eliot M. Lurier | Chief Financial Officer |
| Greg Furrow | Chief Technology Officer, SVP & Head-Quality |
| Albert Paszek | Vice President-Manufacturing Science & Technology |
| Susan E. Ward | Vice President-Clinical Operations |
